ASX:RCE Recce Pharmaceuticals (RCE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Recce Pharmaceuticals Stock (ASX:RCE) 30 days 90 days 365 days Advanced Chart Get Recce Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume630,087 shsAverage VolumeN/AMarket Capitalization$104.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewRecce Pharmaceuticals Ltd, a biotechnology company, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, the company engages in R327 Intravenous which provides serious/life-threatening bacterial infections, including sepsis which is in the phase 1 trial; urinary tract infections, including urosepsis; rapid infusions sepsis in the phase 2 trial; and R327 Topical offers wound infections, including infected burns; and diabetic foot ulcer infections in Phase 2 trails. Further, the company operates various pre-clinical programs, such as Mycobacterium abscessus which is in phase 1 clinical trial; bacterial sinusitis; and additional TBA. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.Read More… Receive RCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recce Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RCE Stock News HeadlinesRecce Pharmaceuticals Extends Entitlement Offer DeadlineApril 30 at 10:25 AM | tipranks.comRecce Pharmaceuticals Updates Securities Issue TimelineApril 30 at 10:25 AM | tipranks.comVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.May 3, 2025 | Stansberry Research (Ad)Break it Down: Recce partners with the US ArmyApril 28, 2025 | msn.comRecce Pharmaceuticals Partners with USAMRIID for Biodefense Pathogen TestingApril 27, 2025 | tipranks.comRecce Pharmaceuticals Updates Investors on Clinical Progress and FundingApril 22, 2025 | tipranks.comRecce Raises $4M from Heavybit and Open-Source Leaders to Bring Data-Native Code Review to Data-Driven Software and AI SystemsApril 22, 2025 | finance.yahoo.comRecce to expand Phase II trial for diabetic foot infectionsApril 22, 2025 | msn.comSee More Headlines RCE Stock Analysis - Frequently Asked Questions How were Recce Pharmaceuticals' earnings last quarter? Recce Pharmaceuticals Ltd (ASX:RCE) announced its earnings results on Wednesday, February, 27th. The company reported ($0.01) earnings per share (EPS) for the quarter. Recce Pharmaceuticals had a negative net margin of 741.65% and a positive trailing twelve-month return on equity of 392.94%. What other stocks do shareholders of Recce Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Recce Pharmaceuticals investors own include ASE Technology (ASX), FlexiGroup Limited (FXL.AX) (FXL), Immutep (IMMP), Mavenir (MVNR), Cronos Group (CRON), Cree (CREE) and Caladrius Biosciences (CLBS). Company Calendar Last Earnings2/27/2019Today5/03/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:RCE CIKN/A Webwww.recce.com.au Phone61 2 8075 4585FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,660,000.00 Net Margins-741.65% Pretax MarginN/A Return on Equity392.94% Return on Assets-238.11% Debt Debt-to-Equity Ratio-8.52 Current Ratio0.34 Quick Ratio4.81 Sales & Book Value Annual Sales$5.03 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow13.57 Book ValueA($0.05) per share Price / BookN/AMiscellaneous Outstanding Shares231,870,000Free FloatN/AMarket Cap$104.34 million OptionableNot Optionable Beta1.05 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (ASX:RCE) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMassive red flag about American consumerWhy is the U.S. Dollar suddenly crashing? Pundits on either side of the aisle have been warning that the U....Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recce Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Recce Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.